The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
News|Slideshows|June 8, 2024
Now Trending: Working Americans Concerned About Future of Medicine, FDA Panel Rejects MDMA
Author(s)Brian Nowosielski
Check out this recap of articles published on our sister sites during the past week.
Advertisement
Explore articles from the past week published on Drug Topics’ sister brands AJMC, Formulary Watch, and Managed Healthcare Executive. From the FDA denying approval for MDMA to the prominence of mental health care in telehealth environments, read up on recent health care industry news.
READ MORE:
Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our
Advertisement
Related to this article
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
3
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
4
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
5